RAREUltragenyx Pharmaceutical Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is RARE?
Ultragenyx Pharmaceutical Inc. keeps −74% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +3.5%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −122% |
| FY2021 | −109% |
| FY2022 | −179% |
| FY2023 | −131% |
| FY2024 | −96% |
| FY2025 | −79% |
Details›
- Operating margin12 months to Q2 2026
- −74%
- Net margin12 months to Q2 2026
- −82%
- Free cash flow margin
- −68%
- R&D as % of revenue
- 108%
- Revenue, trailing twelve months
- $717M
- Free cash flow, trailing twelve months
- −$489M
- Net income, trailing twelve months
- −$586M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.